YOUNGER patients are now eligible for Zostavax to prevent shingles

YOUNGER patients are now eligible for Zostavax to prevent shingles.

Zostavax is now approved by FDA for ages 50 and up...instead of just 60 and up. This will likely be adopted soon by CDC.

This means about 40 million MORE people will be candidates...if you can get the vaccine. Zostavax is still in short supply because Merck is concentrating on making Varivax for chickenpox instead.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote